A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reachedHOCHHAUS, A.Leukemia. 2003, Vol 17, Num 12, pp 2383-2384, issn 0887-6924, 2 p.Article

Current trends in the management of chronic myelogenous leukemiaHEHLMANN, R; HOCHHAUS, A; BERGER, U et al.Annals of hematology (Print). 2000, Vol 79, Num 7, pp 345-354, issn 0939-5555Article

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205HOEHLER, T; VON WICHERT, G; HALLEK, M et al.British journal of cancer. 2013, Vol 109, Num 6, pp 1408-1413, issn 0007-0920, 6 p.Article

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient historyJABBOUR, E; HOCHHAUS, A; CORTES, J et al.Leukemia. 2010, Vol 24, Num 1, pp 6-12, issn 0887-6924, 7 p.Article

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueHOCHHAUS, A; MÜLLER, M. C; LAMBERT, A et al.Leukemia. 2009, Vol 23, Num 9, pp 1628-1633, issn 0887-6924, 6 p.Article

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma : a prospective multicentre phase II trialNEHLS, O; OETTLE, H; GREGOR, M et al.British journal of cancer. 2008, Vol 98, Num 2, pp 309-315, issn 0007-0920, 7 p.Article

Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?KÄLSCH, A.-I; SOBOLETZKI, M; SCHMITT, W. H et al.Clinical and experimental immunology (Print). 2008, Vol 151, Num 3, pp 391-398, issn 0009-9104, 8 p.Article

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseCORTES, J; KIM, D.-W; HOCHHAUS, A et al.Leukemia. 2008, Vol 22, Num 12, pp 2176-2183, issn 0887-6924, 8 p.Article

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-1 trialHOFHEINZ, R.-D; HARTMANN, J. T; HOCHHAUS, A et al.British journal of cancer. 2004, Vol 91, Num 5, pp 834-838, issn 0007-0920, 5 p.Article

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping techniqueKREUZER, K.-A; LE COUTRE, P; LANDT, O et al.Annals of hematology (Print). 2003, Vol 82, Num 5, pp 284-289, issn 0939-5555, 6 p.Article

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantationWASSMANN, B; SCHEURING, U; OTTMANN, O. G et al.Bone marrow transplantation (Basingstoke). 2003, Vol 31, Num 7, pp 611-614, issn 0268-3369, 4 p.Article

Quality assurance in RT-PCR-based BCR/ABL diagnostics: results of an interlaboratory test and a standardization approachBURMEISTER, T; MAURER, J; LÜBBERT, M et al.Leukemia. 2000, Vol 14, Num 10, pp 1850-1856, issn 0887-6924Article

Randomized comparison of interferon-α with busulfant and hydroxyurea in chronic myelogenous leukemiaHEHLMANN, R; HEIMPEL, H; GEORGI, A et al.Blood. 1994, Vol 84, Num 12, pp 4064-4077, issn 0006-4971Article

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia : prolongation of survival by hydroxyureaHEHLMANN, R; HEIMPEL, H; WUSSOW, P. V et al.Blood. 1993, Vol 82, Num 2, pp 398-407, issn 0006-4971Article

A somatic EZH2 mutation in childhood acute myeloid leukemiaERNST, T; PFLUG, A; RINKE, J et al.Leukemia. 2012, Vol 26, Num 7, pp 1701-1703, issn 0887-6924, 3 p.Article

Capecitabine-associated hand―foot―skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancerHOFHEINZ, R.-D; HEINEMANN, V; WEIKERSTHAL, Lf Von et al.British journal of cancer. 2012, Vol 107, Num 10, pp 1678-1683, issn 0007-0920, 6 p.Article

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseGILES, F. J; KANTARJIAN, H. M; HOCHHAUS, A et al.Leukemia. 2012, Vol 26, Num 5, pp 959-962, issn 0887-6924, 4 p.Article

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaHOCHHAUS, A; O'BRIEN, S. G; MONE, M et al.Leukemia. 2009, Vol 23, Num 6, pp 1054-1061, issn 0887-6924, 8 p.Article

The molecular anatomy of the FIP1L1-PDGFRA fusion geneWALZ, C; SCORE, J; BACCARANI, M et al.Leukemia. 2009, Vol 23, Num 2, pp 271-278, issn 0887-6924, 8 p.Article

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibHOCHHAUS, A; BACCARANI, M; NIEDERWIESER, D et al.Leukemia. 2008, Vol 22, Num 6, pp 1200-1206, issn 0887-6924, 7 p.Article

Tumor response to neoadjuvant chemoradiation in rectal cancer : predictor for surgical morbidity?HORISBERGER, K; HOFHEINZ, R. D; PALMA, P et al.International journal of colorectal disease (Print). 2008, Vol 23, Num 3, pp 257-264, issn 0179-1958, 8 p.Article

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer : a study of the CESAR Central European Society for Anticancer Drug Research-EWIVSTEINBILD, S; MROSS, K; BURKHOLDER, I et al.British journal of cancer. 2007, Vol 97, Num 11, pp 1480-1485, issn 0007-0920, 6 p.Article

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaBRANFORD, S; CROSS, N. C. P; HOCHHAUS, A et al.Leukemia. 2006, Vol 20, Num 11, pp 1925-1930, issn 0887-6924, 6 p.Article

Chronic myelogenous leukemia (CML) : resistance to tyrosine kinase inhibitorsHOCHHAUS, A.Annals of oncology. 2006, Vol 17, issn 0923-7534, x274-x279, SUP10Conference Paper

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CMÜLLER, M. C; GATTERMANN, N; KRAUSE, S. W et al.Leukemia. 2003, Vol 17, Num 12, pp 2392-2400, issn 0887-6924, 9 p.Article